Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older who have given written consent approved by an ethics committee
• People who have been diagnosed with a specific type of slow- or moderately-growing neuroendocrine tumour that started in the lung or thymus, and has spread or cannot be surgically removed
• People whose tumour tissue has been examined under a microscope and meets specific classification standards set by the World Health Organization (2015), including measures of how fast the tumour cells are growing
• People whose tumours show up as positive on a specific type of scan that detects a protein called somatostatin receptors (confirm with trial site for full imaging details)
• People whose cancer has shown clear signs of growth or spread on scans within the 12 months before joining the study
• People who have not yet had any systemic (whole-body) cancer treatment, or who have had up to two prior systemic treatments (such as chemotherapy, targeted therapy, or immunotherapy), and whose cancer has continued to grow
• People who have measurable tumours visible on scans at the time of joining the study
• People who have a stored tumour tissue sample from the last 3 years available, or who are able to provide a new biopsy sample if needed
• People who are in good general health, able to carry out normal daily activities with little or no limitation (as rated on a standard medical scale)
• People whose blood counts, liver function, and kidney function meet the required levels based on recent blood tests
• Women who test negative for pregnancy before starting the study, and who agree to use highly effective contraception during treatment and for 6 months after the final dose
• Women who agree not to breastfeed or donate eggs from the start of screening until at least 6 months after the final dose
• Men who agree not to donate sperm from the start of screening until at least 6 months after the final dose
• Men whose partner is pregnant or breastfeeding who agree to use a condom or abstain throughout the study period and for at least 6 months after the final dose
• People who agree not to participate in any other interventional clinical trial while on this study's treatment

Who may not be able to join:

• People who are unable to swallow tablets
• People whose neuroendocrine tumour is classified as poorly differentiated, high-grade, or a mixed tumour type (such as large cell neuroendocrine carcinoma, small cell lung cancer, or adenocarcinoid tumour)
• People who have cancer that has spread to the brain, unless it has been stable on treatment for more than 12 weeks with no signs of pressure on the brain
• People who are still experiencing significant side effects (Grade 2 or higher, except hair loss) from a previous cancer treatment
• People who have been diagnosed with another cancer within the past 12 months, are currently being treated for another cancer, or have any remaining signs of a previously treated cancer
• People with a currently active Hepatitis B or Hepatitis C infection, or a known history of HIV infection
• People who have received a live vaccine within 4 weeks before the first dose of the study treatment
• People who have had a stroke, mini-stroke (TIA), unstable chest pain, heart attack, or significant heart failure symptoms within the 6 months before joining the study
• People who have previously received a type of radiation therapy called PRRT, or certain targeted drugs known as mTOR inhibitors, or a liver-targeted radiation procedure called radio-embolisation within 6 months before joining
• People who have had radiotherapy or major surgery within 12 weeks before the first dose of the study treatment
• People who have received chemotherapy, biological therapies, immunotherapy, or other investigational treatments within 4 weeks before the first dose
• People with a known allergy or sensitivity to the drug Everolimus or any of its ingredients
• People with a known allergy or sensitivity to the drug 177Lu-edotreotide or any of its ingredients, including the protective solution used during its administration
• People with uncontrolled bladder leakage that the trial doctor believes would make safe administration of the study treatment impossible
• People with other medical conditions that the trial doctor believes would prevent them from tolerating or completing the planned treatment

Important: Always verify eligibility with the trial site directly before applying.